Sunshine Biopharma prices, then closes $6.0 million Nasdaq offering
The pharmaceutical company priced a reworked unit offering at $0.55 per share on October 8 and closed the deal the next day through placement agent Aegis Capital Corp.
Sunshine Biopharma Inc. priced a public offering on October 8, 2026 that was made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses1. The deal closed the following day, October 9, 2026, with gross proceeds to the Company of approximately $6 million, before deducting placement agent fees and other expenses payable by the Company1.
The final structure differed from the company's October 2 preliminary filing. The offering consisted of 10,909,083 Common Units (or Pre-Funded Units), each consisting of one share of Common Stock or one Pre-Funded Warrant and two Series D Warrants to purchase one share of Common Stock per warrant at an initial exercise price of $0.661. Pricing was set at $0.55 per Common Unit, or $0.54999 per Pre-Funded Unit1. According to the 8-K, the final split was 10,509,082 common units and 400,000 pre-funded units, and the Pre-Funded Warrants were exercised in full prior to the closing of the Offering1.
The Series D Warrants carry a five-year term, and per the prospectus, their exercise price can adjust downward in a share combination event to a floor of a minimum exercise price of $0.275 (50% of the public offering price per Common Unit)2, subject to Nasdaq stockholder-approval rules.
The registration statement underlying the deal, Form S-1 (No. 333-299274) previously filed with the U.S. Securities and Exchange Commission on October 2, 2026, was declared effective by the SEC on October 7, 20261, and the accompanying prospectus noted on October 9, 2026, the last reported sale price of our common stock was $0.34 per share2, below the $0.6876 close cited in the October 2 filing.
Aegis Capital Corp. acted as exclusive placement agent, receiving a fee of 7% of the public offering price for the Offering and a non-accountable expense allowance of 1% of the public offering price1. Sunshine Biopharma said it plans to use net proceeds for general corporate purposes and working capital1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.